Bisphosphonate resistance in Paget's disease of bone

Arthritis and Rheumatism

Volumn 48, Issue 8, 2003, Pages 2321-2323

  Joshua, Fred ^a   Epstein, Martin ^a   Major, Gabor ^a  

^a ROYAL NEWCASTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; TILUDRONIC ACID;

ADULT; AGED; ARTICLE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; PAGET BONE DISEASE; PREDICTION; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; ANTI-INFLAMMATORY AGENTS; CLODRONIC ACID; DIPHOSPHONATES; DRUG RESISTANCE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; OSTEITIS DEFORMANS;

EID: 0042154228     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11136     Document Type: Article

References (14)

1. Reddy SV, Menaa C, Singer FR, Demulder A, Roodman GD. Cell biology of Paget's disease. J Bone Miner Res 1999;14 Suppl 2:3-8.
2. Van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002;17:465-71.
3. Cooper C, Dennison E, Schafheutle K, Kellingray S, Guyer P, Barker D. Epidemiology of Paget's disease of bone. Bone 1999;24 Suppl:3S-5S.
4. Rogers MJ, Firth JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, et al. Molecular mechanisms of action of bisphosphonates. Bone 1999;24 Suppl:73S-79S.
5. Siris ES. Paget's disease of bone: treatment philosophy for the twenty-first century. Bone 1999;24:55S-56S.
6. Meunier PJ, Vignot E. Therapeutic strategy in Paget's disease of bone. Bone 1995;17 Suppl:489S-491S.
7. Vaile J, Khoo K, Epstein M, Major G. Failure of Paget's disease therapy: is pamidronate resistance simply dose dependent? Proceedings of the Australian and New Zealand Bone and Mineral Society Annual Scientific Meeting; 1996 Oct 2-4; Sydney, Australia. Sydney: ANZBMS, 1997;6:45.
8. Gray RE, Yates AJ, Preston CJ, Smith R, Russell RG, Kanis JA. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med 1987;64:755-67.
9. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996;81:961-7.
10. McClung MR, Tou CK, Goldstein NH, Picot C. Tiludronate therapy for Paget's disease of bone. Bone 1995;17 Suppl: 493S-496S. Erratum in: Bone 1996;18:292.
11. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod WD, Bekker PJ. A randomized double blind comparison of risederonate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999;106:513-20.
12. Cundy T, Wattie D, King AR. High-dose pamidronate in the management of resistant Paget's disease. Calcif Tissue Int 1996;58:6-8.
13. Harinck HIJ, Bijvoet OLM, Blanksma HJ, Dahlinghaus-Nienhuys PJ. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop 1987;217:79-98.
14. Gutteridge DH, Ward LC, Stewart GO, Retallack RW, Will RK, Prince RL, et al. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res 1999;14 Suppl 2:79-84.